266 related articles for article (PubMed ID: 22484816)
1. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
Maione F; Capano S; Regano D; Zentilin L; Giacca M; Casanovas O; Bussolino F; Serini G; Giraudo E
J Clin Invest; 2012 May; 122(5):1832-48. PubMed ID: 22484816
[TBL] [Abstract][Full Text] [Related]
2. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
3. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Cooke VG; LeBleu VS; Keskin D; Khan Z; O'Connell JT; Teng Y; Duncan MB; Xie L; Maeda G; Vong S; Sugimoto H; Rocha RM; Damascena A; Brentani RR; Kalluri R
Cancer Cell; 2012 Jan; 21(1):66-81. PubMed ID: 22264789
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib in pancreatic neuroendocrine tumors.
Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
[TBL] [Abstract][Full Text] [Related]
5. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models.
Maione F; Molla F; Meda C; Latini R; Zentilin L; Giacca M; Seano G; Serini G; Bussolino F; Giraudo E
J Clin Invest; 2009 Nov; 119(11):3356-72. PubMed ID: 19809158
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.
Conley SJ; Gheordunescu E; Kakarala P; Newman B; Korkaya H; Heath AN; Clouthier SG; Wicha MS
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2784-9. PubMed ID: 22308314
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
Capozzi M; VON Arx C; DE Divitiis C; Ottaiano A; Tatangelo F; Romano GM; Tafuto S;
Anticancer Res; 2016 Oct; 36(10):5025-5030. PubMed ID: 27798861
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.
Matsumoto S; Batra S; Saito K; Yasui H; Choudhuri R; Gadisetti C; Subramanian S; Devasahayam N; Munasinghe JP; Mitchell JB; Krishna MC
Cancer Res; 2011 Oct; 71(20):6350-9. PubMed ID: 21878530
[TBL] [Abstract][Full Text] [Related]
9. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
[TBL] [Abstract][Full Text] [Related]
10. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1275-84. PubMed ID: 22084065
[TBL] [Abstract][Full Text] [Related]
11. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.
Diaz R; Nguewa PA; Redrado M; Manrique I; Calvo A
Prostate; 2015 Aug; 75(11):1137-49. PubMed ID: 25893276
[TBL] [Abstract][Full Text] [Related]
13. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
Mankal P; O'Reilly E
Expert Opin Pharmacother; 2013 Apr; 14(6):783-92. PubMed ID: 23458511
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice.
Sennino B; Ishiguro-Oonuma T; Schriver BJ; Christensen JG; McDonald DM
Cancer Res; 2013 Jun; 73(12):3692-703. PubMed ID: 23576559
[TBL] [Abstract][Full Text] [Related]
16. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment.
Burkitt K; Chun SY; Dang DT; Dang LH
Mol Cancer Ther; 2009 May; 8(5):1148-56. PubMed ID: 19435875
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
Duignan IJ; Corcoran E; Pennello A; Plym MJ; Amatulli M; Claros N; Iacolina M; Youssoufian H; Witte L; Samakoglu S; Schwartz J; Surguladze D; Tonra JR
Neoplasia; 2011 Jan; 13(1):49-59. PubMed ID: 21245940
[TBL] [Abstract][Full Text] [Related]
19. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
Broggini T; Wüstner M; Harms C; Stange L; Blaes J; Thomé C; Harms U; Mueller S; Weiler M; Wick W; Vajkoczy P; Czabanka M
Cancer Lett; 2016 Oct; 380(2):568-576. PubMed ID: 26297987
[TBL] [Abstract][Full Text] [Related]
20. Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells.
Cheng ZX; Wang DW; Liu T; Liu WX; Xia WB; Xu J; Zhang YH; Qu YK; Guo LQ; Ding L; Hou J; Zhong ZH
Oncol Rep; 2014 Apr; 31(4):1891-8. PubMed ID: 24535079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
